Article
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Oncotarget - 5 Jul 2016
Fernando Romaine I, Hamilton Duane H, Dominguez Charli, David Justin M, McCampbell Kristen K, Palena Claudia
Abstract excerpt
A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistance, even in patients with EGFR-mutant tumors that initially show substantial clinical responses. This study was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.